Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection

Journal of Clinical Virology

Volumn 48, Issue 4, 2010, Pages 246-250

  Halfon, Philippe ^a,c   Benmoura, Dominique ^a,b   Agostini, Aubert ^b   Khiri, Hacene ^c   Penaranda, Guillaume ^c,d   Martineau, Agnes ^a   Blanc, Bernard ^a  

^a Hospital Ambroise Pare   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c Laboratoire Alphabio   (France)

^d CDL Pharma   (France)

Author keywords

Abbott RealTime High Risk HPV test; Digene Hybrid Capture II; HPV; Roche Linear Array

Indexed keywords

ADULT; AGED; ARTICLE; AUTOMATION; BIOPSY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FRANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; ADOLESCENT; CLASSIFICATION; COMPARATIVE STUDY; DIAGNOSTIC KIT; EVALUATION STUDY; FLUORESCENCE; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; OLIGONUCLEOTIDE PROBE; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROCEDURES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUTOMATION; FEMALE; FLUORESCENCE; FRANCE; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE PROBES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

DIAGNOSTIC KIT; OLIGONUCLEOTIDE PROBE;

EID: 77954658504     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.05.008     Document Type: Article

References (23)

1. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
2. Arbyn M., Ronco G., Cuzick J., Wentzensen N., Castle P.E. How to evaluate emerging technologies in cervical cancer screening?. Int J Cancer 2009, 125(11):2489-2496.
3. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(Suppl. 10):K29-K41.
4. Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E., Glass A.G., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003, 95:46-52.
5. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008, 17:3033-3042.
6. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
7. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-1588.
8. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009, 101:88-99.
9. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124:516-520.
10. Snijders P.J., van den Brule A.J., Meijer C.J. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003, 201:1-6.
11. Meijer C.J., Snijders P.J., Castle P.E. Clinical utility of HPV genotyping. Gynecol Oncol 2006, 103:12-17.
12. Huang Y.K., You S.L., Yuan C.C., Ke Y.M., Cao J.M., Liao C.Y., et al. Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening. Br J Cancer 2008, 98:863-869.
13. Huang S., Tang N., Mak W., Erickson B., Salituro J., Li Y. Principles and analytical performance of Abbott RealTime High Risk HPV test. J Clin Virol 2009, 45:S13-S17.
14. Wentzensen N., Schiffman M., Dunn S.T., Zuna R.E., Walker J., Allen R.A., et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer 2009, 124:964-969.
15. Terry G., Ho L., Londesborough P., Cuzick J., Mielzynska-Lohnas I., Lorincz A. Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol 2001, 65:155-162.
16. Dalstein V., Merlin S., Bali C., Saunier M., Dachez R., Ronsin C. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods 2009, 156:77-83.
17. Huang S., Erickson B., Mak T.N.W., Salituro J., Robinson J., Abravaya K. Clinical performance of Abbott Realtime High Risk HPV test for detection of high-grade cervical intrahepithelial neoplasia in women with abnormal cytology. J Clin Virol 2009, 45:S19-S23.
18. Monsonego J., Pollini G., Evrard M.J., Sednaoui P., Monfort L., Zerat L., et al. Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests. Sex Transm Dis 2008, 35:521-527.
19. Castle P.E., Schiffman M., Burk R.D., Wacholder S., Hildesheim A., Herrero R., et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002, 11:1394-1399.
20. Poljak M., Marin I.J., Seme K., Vince A. Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 2002, 25(Suppl. 3):S89-97.
21. Wright T.C., Huh W.K., Monk B.J., Smith J.S., Ault K., Herzog T.J. Age considerations when vaccinating against HPV. Gynecol Oncol 2008, 109:S40-S47.
22. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079.
23. Tang N., Huang S., Erickson B., Mak W., Salituro J., Robinson J., et al. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. J Clin Virol 2009, 45:S25-S28.